Skip to content
2000
Volume 10, Issue 4
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb / IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb / IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612043453306
2004-02-01
2025-05-03
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612043453306
Loading

  • Article Type:
    Review Article
Keyword(s): Coronary Intervention; GP IIb; IIIa inhibitors
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test